New COPD licence for Fostair. Fostair (formoterol/beclometasone) can now be prescribed for the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.May 1, 2014
